more than half of HLA-identical sibling transplants recipients. Development of aGVHD may decrease the risk of the autoregeneration of thalassemic clones, but severe aGVHD can cause morbidity and mortality; therefore, prevention of severe aGVHD has an important role in post transplant management. Cyclosporin A (CsA) alone and combination of CsA and short-course methotrexate (MTX) are commonly used for GVHD prophylaxis after hematopoietic stem cell transplantation (SCT) since its introduction by the Seattle transplant program in 1986. 1 This regimen consists of CsA daily and MTX on days þ 1, þ 3, þ 6 and þ 11 after transplantation. 1 Recent studies of hematologic malignancies showed that CsA plus short-term MTX compared with CsA alone reduces the incidence, morbidity and mortality of grade III and IV aGVHD and increases overall survival. 2 However, there are few studies examining the prophylaxis of aGVHD in nonmalignant hematologic disorders. 3 In this study, we compared the effects of two different regimens (CsA alone and CsA þ MTX) for aGVHD prophylaxis in thalassmic patients who received hematopoietic SCT from HLA-identical siblings.
Patients and methods

Study design
The major end point of this study was to determine the GVHD prophylaxis efficacy of two different regimens (CsA alone and CsA þ MTX) in thalassemic patients who received hematopoietic SCT from HLA-identical siblings. We also evaluated the kinetics of neutrophil recovery in both groups. Patients with thalassemia major, transplanted in this center since 1991 from HLA-identical sibling donor grafts, were enrolled in this study. The number of patients required to enrol in the study was calculated by a two-sided sample size evaluation method based on the log-rank test. To obtain a study significance level of 0.05 and a study power of 0.80 and assuming an estimated overall survival probability at 48 months of 0.94 for the CsA þ MTX group and 0.78 for CsA group of the study, the sample size required was 140 patients.
Treatment protocol
The pretransplant conditioning regimen in Class I and II consisted of cyclophosphamide (50 mg/kg) for 4 days and busulfan 3.5 mg/kg for 4 days, while conditioning regimen in Class III consisted of cyclophosphamide 40 mg/kg for 4 days and busulfan 4 mg/kg for 4 days. From 1991 to 1997, all patients received CsA þ MTX as GVHD prophylaxis. From 1997 to 2000, the combination regimen was given only to Class III patients according to the hospital protocol. Since 2000, the combination regimen has been given to all patients. Between days À2 and þ 5, patients received CsA alone at a dosage of 3 mg/kg/day followed by 12.5 mg/kg/day when they were able to tolerate oral intake, which was then tapered 5% weekly from þ 60 according to the patient's condition and cyclosporine serum level. In the absence of cGVHD, 6-12 months after BMT, it was discontinued. Mini short-term MTX was given 10 mg/m 2 on day 1 and 6 mg/m 2 on days 3 and 6 post transplantation. In all, 48 of 140 patients were given granulocyte colonysimulating factor (G-CSF) after transplantation to accelerate hematopoietic recovery. In all these patients, G-CSF was started within þ 1 to þ 3 days of blood and marrow infusion. Neutrophil and platelet engraftment were defined as the first of 3 consecutive days, an absolute neutrophil count greater than 0.5 Â 10 9 /l and unsupported platelet greater than 20 Â 10 9 /l. aGVHD and cGVHD were classified according to International Blood and Marrow Transplantation Registry (IBMTR) criteria.
Patients' characteristics
From 1991 to 2001, 140 patients with beta thalassemia major underwent hematopoietic SCT from an HLAidentical sibling in our center. At the time of BMT (SCT), the patients' median age was 6.2 years. Additional details of patient characteristics are reported in Table 1 .
Statistical analysis
aGVHD and cGVHD, overall survival, disease-free survival (DFS) and transplant-related mortality (TRM) were calculated by the Kaplan-Meier method and compared by the log-rank test. To determine differences between groups, we used the Cross tab and w 2 test. In addition, we used the homogeneity test based on Breslow-Day to determine confounding effects.
Results
Graft-versus-host disease
Acute GVHD. Comparing aGVHD between BMT and PBSCT patients showed that it is more common in the BMT group (P ¼ o0.001). We used the homogeneity test depending on Breslow-Day for omitting graft type as a confounding effect. By omitting the confounding effect, CsA/MTX group showed less aGVHD (P ¼ o0.001). Incidence of aGVHD grades I-IV and grades II-IV is shown in Figure 1a and b. There was a suggestion of a higher incidence of aGVHD grades I-IV in CsA group (98%) vs CsA þ MTX group (72.2%), which was statistically significant by w 2 test (P ¼ o0.001 and odds ratio: 1.3). The incidence of aGVHD grades II-IV in CsA group was 78 vs 52.2% in CsA þ MTX group (P ¼ 0.003) ( Table 2) .
Chronic GVHD. In our study, there was no significant difference between the CsA/MTX and CsA groups (36 vs 26.7%, P ¼ 0.24) for cGVHD. Although for PBSCT patients, cGVHD was less in the CsA/MTX group compared with the other group (P ¼ 0.03). In total, 42 patients (30%) (18 in the CsA group and 24 in the CsA/ MTX group) developed cGVHD. A total of 24 patients (17.1%) (13 patients in the CsA group and 11 in the CsA/ MTX group) had limited cGVHD (P ¼ 0.06) and 18 patients (12.9%) (five in the CsA group and 13 in the CsA/MTX group) had extensive cGVHD (P ¼ 0.47) ( Table 2 ). Of the patients with extensive cGVHD, four Cyclosporin A and mini short-term methotrexate M Iravani et al died and 11 (two patients in the CsA group and nine patients in CsA/MTX group) had a Lansky scale between 70 and 50 (mild-to-moderate restriction). Three patients, one in CsA group and two in CsA/MTX group had Lansky scale between 40 and 10 (moderate-to-severe restriction) ( Table 3) .
Engraftment and hematopoietic recovery
Graft failure was documented in seven patients (14%) in the CsA group and in nine patients (10%) in the CsA/MTX group, respectively (P ¼ 0.58). The median time for neutrophil engraftment was 14 days (range 8-37) and 23 days (range 10-62) with or without the administration of G-CSF in the CsA and CsA/MTX groups, respectively (P ¼ o0.001) (Figure 2 ). No significant differences in platelet recovery were observed between the two groups. The median time for PltX20 Â 10 9 /l was 30 (range and 28 (range 9-92) in CsA alone and CsA/MTX groups, respectively (P ¼ 0.48) ( Table 2) .
Transplantation-related mortality
In total, 22 patients died at a median of 96 days after transplantation (range 9-838). Nine patients (18%) were in CsA group and the remaining 13 (14.4%) in the CsA/MTX group (Table 4) . There was no significant difference in the TRM between the two groups (P ¼ 0.58) (Figure 3 ).
Survival
Overall survival and DFS was estimated by the KaplanMeier method. The 5-year overall survival in the CsA and CsA/MTX groups was 77 and 85%, respectively. The 5-year DFS in the CsA and CsA/MTX groups was 58 and 80%, respectively (P ¼ 0.05). In this study, overall survival was not significantly different between the two groups (P ¼ 0.56) (Figure 4a and b) . In all, 105 patients (75%) (35 patients (70%) in CsA group and 70 (77.7%) in the CsA/ MTX group) are alive and transfusion independent.
Discussion
There are numerous protocols for aGVHD prophylaxis. Controlled follow-up studies of CsA show that CsA is not superior to MTX or cyclophosphamide. [6] [7] [8] The equivalent efficacy of CsA and MTX for GVHD prophylaxis and the high incidence of severe aGVHD led to studies evaluating those drugs in combination. Observations confirmed better survival in patients who received CsA þ MTX comparing with either drug alone. In different trials that compared CsA þ MTX to CsA or MTX alone, the combination was accompanied by a significant reduction in aGVHD. The benefit was more pronounced in patient transplanted for aplastic anemia and nonmalignant hematologic disorders compared with those transplanted for leukemia. [9] [10] [11] [12] [13] [14] [15] Other trials show that CsA þ MTX is significantly better than other forms of GVHD prophylaxis in terms of DFS and mentioned that omitting the 11th day of MTX will not cause an increase in mortality and morbidity of aGVHD or the incidence of grade III and IV GVHD, although it may increase the incidence of grade I-IV GVHD. This study was confirmed by Atkinson and Downs. 5 At present, the combination of CsA and MTX is the most widely used regimen for the prophylaxis of aGVHD. Various modifications of the basic regimen developed in Seattle have been investigated. One of them is targeted dose therapy and another one omits the day þ 11 of the MTX in GVHD prophylaxis. There is controversy associated with both and variable results have been reported. 16, 17 Most studies of aGVHD prophylaxis in hematopoietic SCT involve patients with hematologic malignancies in different age categories, although it is different in nonmalignant hematologic disorders, especially thalassemia. Studies from Pescara in patients with thalassemia showed that the incidence of aGVHD grade I was 31% for 39 patients given CsA alone compared with 10% for 67 patients who received CsA and MTX (P ¼ 0.08). In these patients, the impact of aGVHD on morbidity and mortality has been lowered by the young age of the recipients. 18 In our study, the incidence of aGVHD in the CsA þ MTX group is less than for the CsA group (72.2 vs 98% respectively, P ¼ o0.001). Grade II-IV aGVHD in CsA þ MTX and CsA alone groups were 52.2 and 78%, respectively (P ¼ 0.003). Studies by Mrsic and Zikos showed that the incidence of aGVHD was between 35 and 45%, and CsA/MTX was better than CsA alone in GVHD prophylaxis. 10, 19 However, in our study, aGVHD in the CsA group was 98% and in the CsA/MTX group was 72.2%. This may be due to not using MTX in the first group and using a lower dose of MTX in the second group. The lower dose of MTX in our study increased aGVHD grade II-IV compared with the studies in which higher doses and longer duration MTX prophylaxis were used. Nash believed that if the MTX dose was less than 80% of the MTX dose in the short-term MTX regimen, the incidence of aGVHD and its side effects would increase. In the above-mentioned study, the incidence of cGVHD did not differ in CsA and CsA þ MTX groups. Also, extensive cGVHD was not different in the two groups. However, there was no effect on the rate of development of cGVHD, 20 a finding that shows that using or not using MTX does not affect prophylaxis of cGVHD. The occurrence of cGVHD, especially severe, reduces the quality of life in beta thalassemia major patients. This outcome was also shown by Locatelli, Atkinson and Kumus, who did not use MTX or reduced its dose in their studies. In our study, MTX in prophylaxis regimen of aGVHD caused a delay in the engraftment of neutrophils (CsA þ MTX 23 days vs CsA 14 days, P ¼ o0.001). However, there was no difference in platelet engraftment between the two groups. The delay in neutrophil engraftment may raise mortality due to infection. TRM, however, Transplant -related mortality is similar in both groups. The incidence of graft failure was higher in the CsA group compared with the CsA þ MTX group. Our study shows that the CsA and short-term MTX for GVHD prophylaxis regimen can reduce the incidence of grade II-IV aGVHD and improves the probability of survival in patients with thalassemia major undergoing allogeneic blood and marrow transplantation. As severe aGVHD may increase the infection rate and other complications such as graft rejection, it is advisable to reduce the severity of aGVHD in this way.
